Wilmington-based Pharmaceutical Product Development LLC recently introduced a new patient enrollment model “that significantly reduces the time and cost of conducting clinical trials for pharmaceutical and biotechnology customers,” according to a PPD news release.
 
PatientAdvantage inverts the steps of the industry’s long-practiced trial- delivery method, the release stated.
 
“Biopharmaceutical companies typically have used a model that focuses on identifying and starting up sites that are expected to have access to patients with the relevant indication for the trial,” Roger Smith, senior vice president and general manager of PPD’s Accelerated Enrollment Solutions, said in the release.

“Instead of that traditional site-first approach, PatientAdvantage enables us to start by rapidly enrolling community-based patients from our proprietary databases and modeling.," he said. "Then, after mapping patient locations, we select sites to match patient-rich populations. This patient-centric solution is highly predictive and yields greater enrollment and budget certainty.”